Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin
Details : Oritavancin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Skin Diseases, Infectious.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 31, 2022
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Melinta Therapeutics Nabs FDA Nod for More Convenient Rework of Antibiotic Orbactiv
Details : KIMYRSATM (oritavancin) is a single-dose, long-acting lipoglycopeptide antibiotic with rapid bactericidal activity for the treatment of adult patients with ABSSI caused by designated Gram-positive microorganisms, including methicillin-resistant Staphyloc...
Product Name : Orbactiv
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 15, 2021
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients
Details : Oritavancin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Skin Diseases, Infectious.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 14, 2019
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oritavancin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Skin Diseases, Bacterial.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
October 05, 2016
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oritavancin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oritavancin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 15, 2015
Lead Product(s) : Oritavancin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oritavancin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
Details : Oritavancin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 12, 2015
Lead Product(s) : Oritavancin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oritavancin is a Antibiotic drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Skin Diseases, Infectious.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 25, 2015
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oritavancin
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Christchurch Clinical Studies Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers
Details : Oritavancin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 06, 2015
Lead Product(s) : Oritavancin
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Christchurch Clinical Studies Trust
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oritavancin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gram-Positive Bacterial Infections.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 09, 2014
Lead Product(s) : Oritavancin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
